Abstract: Enolase-1 (ENO1) is a key metabolic enzyme in the glycolytic pathway, catalyzing the conversion of 2-phosphoglycerate (2-PGA) to phosphoenolpyruvate (PEP). It also possesses multiple functions, including plasminogen receptor and RNA-binding protein. In recent years, numerous studies have demonstrated that ENO1 is universally overexpressed in various solid tumors and hematologic malignancies, suggesting its biological and clinical significance in tumor development. Given the pivotal role of ENO1 in tumor metabolic reprogramming and malignant tumor progression, further investigation into its functions and mechanisms may provide a basis for identifying novel prognostic markers and therapeutic targets. This article will focus on reviewing the research progress, mechanisms of action, and molecular pathways of ENO1 in hematologic malignancies such as acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL), and multiple myeloma (MM), and introduce the potential application prospects of specific enolase inhibitors (ENOblock) in antitumor therapy.

Key words: enolase-1, inhibitor of enolase, hematological malignancies, glycolysis